Cannabis researcher MedPharm has been granted funding to study the effect of phytocannabinoids — naturally occurring chemicals, called cannabinoids, from marijuana plants — on Alzheimer’s disease, with the ultimate aim of treatment development. The new funding comes from the Colorado State University Institute of Cannabis Research (ICR). It was…
The first patient has been dosed in an open-label dose optimization trial of bryostatin, an investigational treatment for Alzheimer’s disease. According to the therapy’s developer, Synaptogenix — previously called Neurotrope — the dose-finding trial will prepare the company to move forward with bryostatin’s next phase of clinical…
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Amyloid Plasma Panel, Roche’s blood-based biomarker test designed to enable earlier Alzheimer’s disease diagnoses. Breakthrough device designation is granted to medical devices that provide a more effective way of treating or diagnosing a life-threatening…
Assisted Living Locators, a nationwide placement and referral service for seniors, is again set to support the Walk to End Alzheimer’s, touted as the world’s largest event to raise awareness and funds for Alzheimer’s disease care, support, and research. The event is presented by the Alzheimer’s Association…
Residents in the Dallas/Fort Worth area of Texas will be among the first to have access to a minimally invasive diagnostic test for Alzheimer’s disease. The DISCERN test, by SYNAPS Dx (SDx), will be commercially launched in Texas because of the state’s relatively high number of people…
A large clinical trial has received $45 million in U.S. funding to evaluate the efficacy of benfotiamine — a lab-made precursor of thiamine or vitamin B1 — in slowing the cognitive decline of those with mild Alzheimer’s disease or mild cognitive impairment. The five-year grant was awarded by the…
Repeated dosing of ACD856, an investigational therapy for Alzheimer’s disease, was generally safe and well tolerated in healthy adult volunteers, according to data from a now-completed Phase 1 trial. AlzeCure Pharma is developing ACD856 as its lead therapeutic candidate in the company’s NeuroRestore platform, which contains investigational therapies for…
The toxic clumping of amyloid-beta, one of two key proteins implicated in Alzheimer’s disease, causes living human cells to generate heat, which may cause more clumps to form, a study suggests. “Overheating a cell is like frying an egg — as it heats up, the proteins start to clump…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Eisai seeking accelerated approval of lecanemab (BAN2401), an investigational amyloid-targeting antibody to treat early Alzheimer’s disease in people with confirmed amyloid plaques in the brain. Eisai finished the rolling application a few months ago.
The author of a new book on Alzheimer’s disease is raising questions about whether aging should be more of a concern when it comes to U.S. political leaders. “Age is the biggest risk factor for developing Alzheimer’s disease,” stated a press release from author Lisa Skinner, announcing the…
Get regular updates to your inbox.